Palliative Care for Patients With Breast Cancer in a Palliative Care Unit of a Japanese Hospital.

Autor:	Nakata B; Surgery, Kashiwara Municipal Hospital, Kashiwara, JPN., Sakimura C; Surgery, Kashiwara Municipal Hospital, Kashiwara, JPN., Tendo M; Surgery, Kashiwara Municipal Hospital, Kashiwara, JPN., Tsukida T; Surgery, Kashiwara Municipal Hospital, Kashiwara, JPN., Hori T; Surgery, Kashiwara Municipal Hospital, Kashiwara, JPN., Hirakawa K; Surgery, Kashiwara Municipal Hospital, Kashiwara, JPN., Ishikawa T; Surgery, Kashiwara Municipal Hospital, Kashiwara, JPN.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Aug 26; Vol. 16 (8), pp. e67834. Date of Electronic Publication: 2024 Aug 26 (Print Publication: 2024).
DOI:	10.7759/cureus.67834
Abstrakt:	Background This study describes the end-of-life care management in palliative care units (PCUs) for patients with breast cancer in Japan. Methods The medical data of patients admitted to the palliative care unit of Kashiwara Municipal Hospital between October 2017 and December 2023 were analyzed. A chi-square test was conducted to analyze the data using the Excel software (Microsoft Corp., Redmond, WA). Results The most common clinical condition among the 32 patients with breast cancer in our palliative care unit was pleural effusion (17/32, 53.1%), followed by obstructive jaundice (6/32, 18.8%), disseminated intravascular coagulation (DIC) (4/32, 12.5%), and hypercalcemia (1/32, 3.1%). Most patients had no indications for pleural effusion removal, biliary drainage, or anticoagulation therapy. Palliative sedation was performed in 25% of the patients with breast cancer, mainly to relieve intolerable general fatigue. There were no statistically significant differences in the sedation ratios between breast cancer and cancers at other primary sites. Conclusion Palliative treatments using appropriate infusion, narcotics, oxygen administration, various drugs, and sedation were administered in our palliative care unit to relieve symptoms instead of radical treatments for severe clinical conditions of breast cancer. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. The Ethics Committee of Kashiwara Municipal Hospital issued approval 2024-2. This study was approved by the Ethics Committee of Kashiwara Municipal Hospital. The opt-out document was posted in the outpatient waiting room and wards of Kashiwara Municipal Hospital, in which the patients were assured of their right to refuse and to withdraw from the study at any stage. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Nakata et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu